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The prevalence of antibiotic resistance is important information
commonly relied on when choosing empirical antibiotic
regimens. But too much is being asked of these laboratory data,
which should not dictate empirical antibiotic regimens.
Laboratory determined antibiotic resistance rates are a product
of policies for the microbiological testing of infections and
antibiotic resistance in the population.1 This is particularly true
for urinary tract infections (UTIs).2 In the UK urine
microbiology is not routinely recommended for patients with
good evidence of a UTI.3However, it is recommended that UTIs
are investigated microbiologically when antibiotic treatment
has failed.3 The potential for biasing of resistance rates is
therefore high, making the Infectious Disease Society of
America’s recommendation against empirical use of an antibiotic
with a resistance rate greater than 20% difficult to justify.4
Indeed, such a policy may exacerbate the problem of antibiotic
resistance by unnecessarily increasing the use of broader
spectrum antibiotics.
It is important we acknowledge that the best data for choosing
empirical antibiotics regimens are not laboratory reported
resistance rates but clinical cure rates in the populations the
antibiotics are recommended for. Such data are costly to obtain
but would not be biased by testing algorithms, limitations over
the criteria determining susceptibility and resistance, individual
pharmacokinetics, misdiagnosis, and the potential for patients
to improve without medical intervention. National antibiotic
resistance surveillance programmes do not currently determine
clinical cure rates, but these data could help limit the use of
broad spectrum antibiotics.
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